Merck Announces Week 96 Data from Phase 2b Study Evaluating Islatravir With Doravirine for HIV-1

▴ Merck Announces Week 96 Data from Phase 2b Study Evaluating Islatravir With Doravirine for HIV-1
Merck, today announced Week 96 data from the Phase 2b trial evaluating the efficacy and safety of islatravir for HIV-1 infections

Merck, known as MSD outside the United States and Canada, today announced Week 96 data from the Phase 2b trial (NCT03272347) evaluating the efficacy and safety of islatravir, the company’s investigational oral nucleoside reverse transcriptase translocation inhibitor (NRTTI), in combination with doravirine (PIFELTR), in treatment-naïve adults with HIV-1 infection.

“Our commitment to medical advances in HIV can be seen in the important data we are presenting at HIV Glasgow 2020, including islatravir’s potential for use in combination with doravirine as a once-daily, two-drug treatment. In addition, we are presenting data on MK-8507, which is advancing to Phase 2 investigations in combination with islatravir as a once-weekly oral regimen,” said Dr. Joan Butterton, vice president, infectious diseases, Global Clinical Development, Merck Research Laboratories. “We continue to pursue new methods for treating HIV, as shown by our growing body of clinical research, and we look forward to sharing new data from our ongoing, global Phase 3 clinical trials for islatravir with doravirine in the future.”

Tags : #LatestMerckNewsOct8 #LatestPharmanewsoct8 #treatmentforHIV1infection #islatravirwithdoravirine

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

The Bitter Truth Behind Sweet Treats: Hidden Cancer Risks in Your Favorite CakesOctober 03, 2024
Ageing Faster Than You Think? Discover How a Simple Cheek Swab Could Save Your LifeOctober 03, 2024
The University of Tasmania invites international student applications for their Tasmanian International ScholarshipOctober 03, 2024
A New Hope for Type 1 Diabetes: Tackling Blood Sugar Drops with Somatostatin BlockersOctober 03, 2024
Prostate Cancer Strikes Young: The Alarming Rise of Aggressive Cases in Men Under 50October 03, 2024
Fleetguard Filters Private Limited (FFPL) Wins Prestigious ‘Iconic Brands of India 2024’ at the This recognition adds to Fleetguard's growing list of accolades, further establishing its position as a leader in the automotive industry. The company remains dedicated to advancing innovation and providing solutions that consistently meet the changing needs of its customers.October 03, 2024
Mr. Piush Srivastava, Head of Marketing and Corporate Communications of Fleetguard Filters Pvt. Ltd, Awarded 'Marketing Maverick' by Dun & Bradstreet October 01, 2024
Chikungunya Strikes Back: The Forgotten Virus Making a Deadly ComebackOctober 01, 2024
The Hidden Cancer Risk in Your Morning Routine: How Poor Oral Hygiene May Be Endangering Your HealthOctober 01, 2024
Toxic Wrappings: Is Your Food Packaging Linked to Breast Cancer?September 30, 2024
My body, Is it my own?September 30, 2024
A Cure for Type 1 Diabetes? The Game-Changing Power of Stem Cell TherapySeptember 30, 2024
The Future of Health: Why Ayurveda's Inclusion in Ayushman Bharat is a MilestoneSeptember 30, 2024
Nutriwiz Launches Affordable Milk Mixes to Combat Micronutrient Deficiencies at ISF 2024September 28, 2024
World Heart Day- Tetsuya Yamada - Managing Director, OMRON Healthcare India.September 28, 2024
Amritapuri Celebrates Amma's 71st BirthdaySeptember 28, 2024
Is Poor Sleep During Pregnancy Setting Your Baby Up for Developmental Challenges?September 28, 2024
Can India Save Modern Medicine? The War Against Antimicrobial Resistance Begins HereSeptember 28, 2024
Mpox Clade I: The Deadly Virus India's Fighting to ContainSeptember 28, 2024
From Desk to Date: Quick Hair Transformations for busy ProfessionalsSeptember 27, 2024